Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D., Hosszu, K., Cancio, M. I., Jakubowski, A. A., Scaradavou, A., Boelens, J. J., Sauter, C. S., Perales, M.-A., Giralt, S. A., Taylor, C., Chaudhari, J., Wang, X., Rivière, I., … Curran, K. J. (2025). Allogeneic Off-the-Shelf CAR T-Cell Therapy for Relapsed or Refractory B-Cell Malignancies. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015157

Lopez, J., Powles, T., Braiteh, F., Siu, L. L., LoRusso, P., Friedman, C. F., Balmanoukian, A. S., Gordon, M., Yachnin, J., Rottey, S., Karydis, I., Fisher, G. A., Schmidt, M., Schuler, M., Sullivan, R. J., Burris, H. A., Galvao, V., Henick, B. S., Dirix, L., … Camidge, D. R. (2025). Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine, 31(1), 152–164. https://doi.org/10.1038/s41591-024-03334-7

Stein, M. N., Dumbrava, E. E., Teply, B. A., Gergis, U. S., Guiterrez, M. E., Reshef, R., Subudhi, S. K., Jacquemont, C. F., Senesac, J. H., Bayle, J. H., Scripture, C. D., Chatwal, M. S., Bilen, M. A., Stadler, W. M., & Becerra, C. R. (2024). PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-53220-6

Dimitriou, F., Orloff, M. M., Koch Hein, E. C., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., Gaudy-Marqueste, C., Grob, J.-J., Michielin, O., Hamid, O., Long, G. V., Sullivan, R., Kapiteijn, E., Johnson, D. B., Ascierto, P. A., … Dummer, R. (2025). Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. European Journal of Cancer, 214, 115161. https://doi.org/10.1016/j.ejca.2024.115161

Davar, D., Williams, A., Lopez, J., Olson, D., Sato, T., Shaw, H., Friedman, C. F., Thistlethwaite, F., Middleton, M., Lebbe, C., Ma, V. T., Izar, B., Lau, P., Bechter, O., Kirk, P., Yuan, Y., Marshall, S., & Hamid, O. (2024). 694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). Regular and Young Investigator Award Abstracts, A796–A796. https://doi.org/10.1136/jitc-2024-sitc2024.0694

Luthria, K., Shah, P., Caldwell, B., Melms, J. C., Abuzaid, S., Jakubikova, V., Brodtman, D. Z., Bose, S., Amin, A. D., Ho, P., Biermann, J., Tagore, S., Ingham, M., Schwartz, G. K., & Izar, B. (2024). Single-cell profiling of sarcomas from archival tissue reveals programs associated with resistance to immune checkpoint blockade. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-2976

Zaidi, S., Park, J., Chan, J. M., Roudier, M. P., Zhao, J. L., Gopalan, A., Wadosky, K. M., Patel, R. A., Sayar, E., Karthaus, W. R., Kates, D. H., Chaudhary, O., Xu, T., Masilionis, I., Mazutis, L., Chaligné, R., Obradovic, A., Linkov, I., Barlas, A., … Sawyers, C. L. (2024). Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies. Proceedings of the National Academy of Sciences, 121(28). https://doi.org/10.1073/pnas.2322203121

Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Dhodapkar, M. V. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42(22), 2702–2712. https://doi.org/10.1200/jco.24.01008

Keller, M. D., Hanley, P. J., Chi, Y.-Y., Aguayo-Hiraldo, P., Dvorak, C. C., Verneris, M. R., Kohn, D. B., Pai, S.-Y., Dávila Saldaña, B. J., Hanisch, B., Quigg, T. C., Adams, R. H., Dahlberg, A., Chandrakasan, S., Hasan, H., Malvar, J., Jensen-Wachspress, M. A., Lazarski, C. A., Sani, G., … Pulsipher, M. A. (2024). Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47057-2

Vadivel, C. K., Willerslev-Olsen, A., Namini, M. R. J., Zeng, Z., Yan, L., Danielsen, M., Gluud, M., Pallesen, E. M. H., Wojewoda, K., Osmancevic, A., Hedebo, S., Chang, Y.-T., Lindahl, L. M., Koralov, S. B., Geskin, L. J., Bates, S. E., Iversen, L., Litman, T., Bech, R., … Buus, T. B. (2024). Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome. Blood, 143(15), 1496–1512. https://doi.org/10.1182/blood.2023021671

Gordon, E. R., Adeuyan, O., Kwinta, B. D., Schreidah, C. M., Fahmy, L. M., Queen, D., Trager, M. H., Magro, C. M., & Geskin, L. J. (2024). Exploring cutaneous lymphoproliferative disorders in the wake of COVID‐19 vaccination. Skin Health and Disease, 4(3). Portico. https://doi.org/10.1002/ski2.367

Hu, X., Bukhari, S. M., Tymm, C., Adam, K., Lerrer, S., Henick, B. S., Winchester, R. J., & Mor, A. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer, 12(3), e008482. https://doi.org/10.1136/jitc-2023-008482

Hilton, J. F., Ott, P. A., Hansen, A. R., Li, Z., Mathew, M., Messina, C. H., Dave, V., Ji, X., Karpinich, N. O., Hirschfeld, S., Ballas, M., & Zandberg, D. P. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 73(3). https://doi.org/10.1007/s00262-023-03623-z

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J., Korn, R., Peng, W., Lui, C., … Jacobson, C. A. (2024). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood, 143(6), 496–506. https://doi.org/10.1182/blood.2023021243

Pemmaraju, N., Cuglievan, B., Lasky, J., Kheradpour, A., Hijiya, N., Stein, A. S., Meshinchi, S., Mullen, C. A., Angelucci, E., Vinti, L., Mughal, T. I., & Pawlowska, A. B. (2024). Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients. EJHaem, 5(1), 61–69. Portico. https://doi.org/10.1002/jha2.856

Verma, A., Chi, Y.-Y., Malvar, J., Lamble, A., Chaudhury, S., Agarwal, A., Li, H.-T., Liang, G., Leong, R., Brown, P. A., Kaplan, J., Schafer, E. S., Slone, T., Pauly, M., Chang, B. H., Stieglitz, E., Wayne, A. S., Hijiya, N., & Bhojwani, D. (2024). Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers, 16(3), 496. https://doi.org/10.3390/cancers16030496

Ko, B., Tao, K., Brennan, L., Rakhade, S., Chan, C. X., Moone, J.-Y., Zhu, R., Sher, A., Wang, S., Bracero, Y., Fullerton, B., McLellan, B., Geskin, L. J., & Saenger, Y. M. (2024). Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients. Melanoma Research, 34(2), 134–141. https://doi.org/10.1097/cmr.0000000000000945

Cherng, H.-J. J., & Herrera, A. (2024). Now You “CD20,” Now You Don’t: A Vanishing Act in B-cell Lymphomas After Bispecific Antibody Treatment. The Hematologist, 21(2). https://doi.org/10.1182/hem.v21.2.202425

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787

Pazos, M., Estrella, B., Piorczynski, T. B., Tolu, S. S., Huang, W., Ryu, Y. K., & Amengual, J. E. (2023). First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL. Blood, 142(Supplement 1), 4184–4184. https://doi.org/10.1182/blood-2023-186639

Cherng, H.-J. J., Yang, X., Yancey, R., Gordillo, C. A., Piorczynski, T. B., Chan, H. T., Ofori, K. N., Bhagat, G., Califano, A., Pro, B., Booher, K., Amengual, J. E., Reshef, R., & Sina, A. A. I. (2023). Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes. Blood, 142(Supplement 1), 4371–4371. https://doi.org/10.1182/blood-2023-178376

Gong, Z., Umoru, G., Monge, J., Shah, N., Mohyuddin, G. R., Radhakrishnan, S., Chakraborty, R., Schinke, C., D’Souza, A., & Mohan, M. (2023). Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study. Blood, 142(Supplement 1), 358–358. https://doi.org/10.1182/blood-2023-182695

Al Malki, M. M., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., Macbeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation. Blood, 142(Supplement 1), 2090–2090. https://doi.org/10.1182/blood-2023-187355

Durot, E., Roos-Weil, D., Chauchet, A., Decroocq, J., Di Blasi, R., Gastinne, T., Bensader, H., Cheminant, M., Jacquet, C., Guidez, S., Gros, F.-X., Bachy, E., Cony-Makhoul, P., Treon, S. P., Delmer, A. J., Reshef, R., Le Gouill, S., Castillo, J. J., & Houot, R. (2023). CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study. Blood, 142(Supplement 1), 616–616. https://doi.org/10.1182/blood-2023-173988

Akahoshi, Y., Spyrou, N., Weber, D., Aguayo-Hiraldo, P., Ayuk, F. A., Bunworasate, U., Choe, H., Eder, M., Etra, A., Grupp, S., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kraus, S., Merli, P., Qayed, M., Reshef, R., Schechter-Finkelstein, T., Ullrich, E., … Nakamura, R. (2023). Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study. Blood, 142(Supplement 1), 776–776. https://doi.org/10.1182/blood-2023-181900

Mejia Saldarriaga, M., Unkenholz, C., Fein, J. A., Monge, J., Rosenbaum, C., Pearse, R., Mapara, M., Inghirami, G., Lentzsch, S., Reshef, R., Niesvizky, R., & Bustoros, M. (2023). Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities. Blood, 142(Supplement 1), 3341–3341. https://doi.org/10.1182/blood-2023-187832

Midha, S., Gurumurthi, A., Costello, P., Redd, R. A., Freeman, C. L. L., Castaneda, O., Gonzalez, R., Ionescu, F., Gaballa, M., Kalariya, N., Khouri, J., Dima, D., Kocoglu, M. H., Sborov, D., Wagner, C. B., Atrash, S., Voorhees, P. M., Hashmi, H., Davis, J. A., … Patel, K. K. (2023). Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma. Blood, 142(Supplement 1), 3499–3499. https://doi.org/10.1182/blood-2023-187565

DiPersio, J., Cooper, B. W., Suh, H. C., Koura, D., Bernard, L., Shah, N. N., Walter, R. B., Perales, M.-A., Mapara, M., Tamari, R., Loken, M. R., Breitschwerdt, K., Nath, S., Raffel, G. D., & Koehne, G. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood, 142(Supplement 1), 483–483. https://doi.org/10.1182/blood-2023-190037

Xu-Monette, Z. Y., Li, Y., Snyder, T., Yu, T., LU, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F., Go, H., Ponzoni, M., Ferreri, A. J. M., Møller, M., … Young, K. H. (2023). Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 429–429. https://doi.org/10.1182/blood-2023-179972

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Peng, W., Lui, C., Wulff, J., … Jacobson, C. A. (2023). Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. Blood, 142(Supplement 1), 4868–4868. https://doi.org/10.1182/blood-2023-174914

McNerney, K. O., Fabrizio, V. A., Talleur, A. C., Si Lim, S., Dreyzin, A., Baggott, C., Vatsayan, A., Rossoff, J., Prabhu, S., Pacenta, H. L., Phillips, C. L., Talano, J.-A., Moskop, A., Verneris, M. R., Myers, D., Karras, N., Bonifant, C. L., Qayed, M., Hermiston, M. L., … Naik, S. (2023). Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia. Blood, 142(Supplement 1), 2133–2133. https://doi.org/10.1182/blood-2023-189921

Malki, M. A., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., MacBeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). 682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0682

Adeuyan, O., Gordon, E. R., Lapolla, B. A., Schreidah, C. M., Fahmy, L. M., Chen, C., & Geskin, L. J. (2023). 254 Cutaneous T-cell lymphoma and atopic dermatitis: a tale of two inflammatory skin conditions from a single cell RNA sequencing perspective. Journal of Investigative Dermatology, 143(11), S375. https://doi.org/10.1016/j.jid.2023.09.262

Migden, M. R., Chai-Ho, W., Daniels, G. A., Wise-Draper, T. M., Kheterpal, M., Tang, J. C., Bolotin, D., Verschraegen, C., Poklepovic, A. S., Khan, S. A., Ibrahim, S. F., Zeitouni, N. C., Medina, T., Tsai, K. K., Tucci, C., Navia, S., Donthireddy, L., Bommareddy, P. K., Hou, J. W., & Davar, D. (2023). 777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS). Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0777

Liu, J., O’Malley, D., Nieuwenhuysen, E. V., Moore, K., Hamilton, E., Yeku, O., Bouberhan, S., Hou, J., Schröder, D., Wang, B., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Lowy, I., Uldrick, T., Miller, E., & O’Cearbhaill, R. (2023). PO011LBA/#1512  Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results. Plenary 03: Oral Abstract Presentations – Ovarian Cancer. https://doi.org/10.1136/ijgc-2023-igcs.11

Barsan, V., Li, Y., Prabhu, S., Baggott, C., Nguyen, K., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H., Talano, J.-A., Moskop, A., Baumeister, S., Verneris, M. R., Myers, G. D., Karras, N. A., Cooper, S., Qayed, M., Hermiston, M., Satwani, P., … Schultz, L. M. (2023). Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine, 65, 102268. https://doi.org/10.1016/j.eclinm.2023.102268

Ventin, M., Cattaneo, G., Jia, J., Arya, S., Maggs, L., Sun, Y., Boland, G. M., Jenkins, R. W., Ksander, B. R., Haq, R., Wang, X., Ryeom, S., Ferrone, C. R., & Ferrone, S. (2023). 317 B7-H3-targeted CAR T cell with an inducible caspase 9 suicide gene effectively eradicates uveal melanoma liver metastases. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0317

Eylon, M., Prabhu, S., John, S., King, M. J. M., Bhatt, D., Curran, K. J., Erickson, C., Karras, N. A., Phillips, C. L., Satwani, P., Hermiston, M., Southworth, E., Baumeister, S. H. C., Talano, J.-A., MacMillan, M. L., Rossoff, J., Bonifant, C. L., Myers, G. D., Rouce, R. H., … Schultz, L. M. (2023). Mediport use as an acceptable standard for CAR T cell infusion. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1239132

Jain, M. D., Miklos, D. B., Jacobson, C. A., Timmerman, J. M., Sun, J., Nater, J., Fang, X., Patel, A., Davis, M., Heeke, D., Trinh, T., Mattie, M., Neumann, F., Kim, J. J., To, C., Filosto, S., & Reshef, R. (2023). Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. Clinical Cancer Research, 29(20), 4118–4127. https://doi.org/10.1158/1078-0432.ccr-23-0916

Wei, A. Z., Chen, L. N., Orloff, M., Ariyan, C. E., Asgari, M., Barker, C. A., Buchbinder, E., Chandra, S., Couts, K., Frumovitz, M. M., Futreal, A., Gershenwald, J. E., Hanna, E. Y., Izar, B., LeBlanc, A. K., Leitao, M. M., Lipson, E. J., Liu, D., McCarter, M., … Carvajal, R. D. (2023). Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell & Melanoma Research, 36(6), 542–556. Portico. https://doi.org/10.1111/pcmr.13139

Wilky, B., Trent, J. C., Gordon, M., El-Khoueiry, A. B., Bullock, A., Henick, B. S., Schwartz, G. K., Agulnik, M., Mahadevan, D., Patel, J., Grossman, J., Rosenthal, K., O’Day, S. J., & Tsimberidou, A. M. (2023). 1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma. Annals of Oncology, 34, S1032–S1033. https://doi.org/10.1016/j.annonc.2023.09.1148

Orloff, M., Watkins, C., Carvajal, R. D., Shoushtari, A. N., Sacco, J. J., Schlaak, M., Gama, J., & Butler, M. O. (2023). 1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up. Annals of Oncology, 34, S678. https://doi.org/10.1016/j.annonc.2023.09.2263

Ager, C. R., Zhang, M., Chaimowitz, M., Bansal, S., Tagore, S., Obradovic, A., Jugler, C., Rogava, M., Melms, J. C., McCann, P., Spina, C., Drake, C. G., Dallos, M. C., & Izar, B. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer, 11(9), e006782. https://doi.org/10.1136/jitc-2023-006782

Karimi, Y., Ghesquieres, H., Jurczak, W., Cheah, C. Y., Clausen, M. R., Lugtenburg, P., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Stirner, M. C., Liu, Y., … Thieblemont, C. (2023). POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00718-8

Kim, W.-S., Shortt, J., Luigi Zinzani, P., Mikhaylova, N., Marin-Niebla, A., Radeski, D., Ribrag, V., Domingo Domènech, E., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY. HemaSphere, 7(S3), e6843062. https://doi.org/10.1097/01.hs9.0000971464.68430.62

Flinn, I. W., Jacobson, C., Nastoupil, L. J., Morschhauser, F., Davies, A. J., Buske, C., Corradini, P., Lopez-Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 7(S3), e6350662. https://doi.org/10.1097/01.hs9.0000971324.63506.62

Kris Michael, M., Robert, B., Amer, B., Sridhar, C., Choquet, S., Dierickx, D., Rajani, D., Gamelin, L., Ghobadi, A., Norma, G.-B., Manher, J., Aditi, M., Sarah, N., Ran, R., Wei, Y., & Susan, P. (2023). P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE). HemaSphere, 7(S3), e0490265. https://doi.org/10.1097/01.hs9.0000972448.04902.65

Mehta-Shah, N., Jacobsen, E., Luigi Zinzani, P., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L., Izutsu, K., Waters, S., Brammer, J., Pro, B., & Horwitz, S. (2023). P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY. HemaSphere, 7(S3), e3891642. https://doi.org/10.1097/01.hs9.0000971392.38916.42

Senna, M., Forman, S., Bordone, L., De La Cueva Dobao, P., Wolk, R., Zwillich, S., Zhang, F., Mohamed Ahmed, H., & Takiya, L. (2023). Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study. SKIN The Journal of Cutaneous Medicine, 7(4), s224. https://doi.org/10.25251/skin.7.supp.224

Di Meo, F., Iyer, A., Akama, K., Cheng, R., Yu, C., Cesarano, A., Kurihara, N., Tenshin, H., Aljoufi, A., Marino, S., Soni, R. K., Roda, J., Sissons, J., Vu, L. P., Guzman, M., Huang, K., Laskowski, T., Broxmeyer, H. E., Roodman, D. G., & Perna, F. (2023). A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports Medicine, 4(7), 101110. https://doi.org/10.1016/j.xcrm.2023.101110